IL206409A0 - ALTERNATIVE SCAFFOLD PROTEIN FUSIONS PHAGE DISPLAY VIA FUSION TO pIX OF M13 PHAGE - Google Patents

ALTERNATIVE SCAFFOLD PROTEIN FUSIONS PHAGE DISPLAY VIA FUSION TO pIX OF M13 PHAGE

Info

Publication number
IL206409A0
IL206409A0 IL206409A IL20640910A IL206409A0 IL 206409 A0 IL206409 A0 IL 206409A0 IL 206409 A IL206409 A IL 206409A IL 20640910 A IL20640910 A IL 20640910A IL 206409 A0 IL206409 A0 IL 206409A0
Authority
IL
Israel
Prior art keywords
phage
pix
display via
scaffold protein
protein fusions
Prior art date
Application number
IL206409A
Original Assignee
Centocor Ortho Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centocor Ortho Biotech Inc filed Critical Centocor Ortho Biotech Inc
Publication of IL206409A0 publication Critical patent/IL206409A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1044—Preparation or screening of libraries displayed on scaffold proteins

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL206409A 2007-12-19 2010-06-16 ALTERNATIVE SCAFFOLD PROTEIN FUSIONS PHAGE DISPLAY VIA FUSION TO pIX OF M13 PHAGE IL206409A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1477807P 2007-12-19 2007-12-19
PCT/US2008/087696 WO2009086116A2 (en) 2007-12-19 2008-12-19 Alternative scaffold protein fusions phage display via fusion to plx of m13 phage

Publications (1)

Publication Number Publication Date
IL206409A0 true IL206409A0 (en) 2010-12-30

Family

ID=40825038

Family Applications (1)

Application Number Title Priority Date Filing Date
IL206409A IL206409A0 (en) 2007-12-19 2010-06-16 ALTERNATIVE SCAFFOLD PROTEIN FUSIONS PHAGE DISPLAY VIA FUSION TO pIX OF M13 PHAGE

Country Status (6)

Country Link
EP (1) EP2238247A2 (en)
JP (1) JP2011507529A (en)
AU (1) AU2008345674A1 (en)
CA (1) CA2709994A1 (en)
IL (1) IL206409A0 (en)
WO (1) WO2009086116A2 (en)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004296376B2 (en) 2003-12-05 2010-03-04 Bristol-Myers Squibb Company Inhibitors of type 2 vascular endothelial growth factor receptors
US20080124355A1 (en) 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
US8470332B2 (en) 2006-11-22 2013-06-25 Bristol-Myers Squibb Company Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IR
MX2010008874A (en) 2008-02-14 2010-09-22 Bristol Myers Squibb Co Targeted therapeutics based on engineered proteins that bind egfr.
AR071874A1 (en) 2008-05-22 2010-07-21 Bristol Myers Squibb Co ARMAZON DOMAIN PROTEINS BASED ON MULTIVALENT FIBRONECTINE
US8647642B2 (en) 2008-09-18 2014-02-11 Aviex Technologies, Llc Live bacterial vaccines resistant to carbon dioxide (CO2), acidic PH and/or osmolarity for viral infection prophylaxis or treatment
AU2009308935B2 (en) 2008-10-31 2015-02-26 Janssen Biotech, Inc. Fibronectin type III domain based scaffold compositions, methods and uses
TWI496582B (en) 2008-11-24 2015-08-21 必治妥美雅史谷比公司 Bispecific egfr/igfir binding molecules
US8241623B1 (en) 2009-02-09 2012-08-14 David Bermudes Protease sensitivity expression system
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
US8771669B1 (en) 2010-02-09 2014-07-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
PT2571531T (en) * 2010-04-30 2016-08-31 Janssen Biotech Inc Stabilized fibronectin domain compositions, methods and uses
TW201138808A (en) 2010-05-03 2011-11-16 Bristol Myers Squibb Co Serum albumin binding molecules
WO2011150133A2 (en) 2010-05-26 2011-12-01 Bristol-Myers Squibb Company Fibronectin based scaffold proteins having improved stability
PL2697257T3 (en) 2011-04-13 2017-04-28 Bristol-Myers Squibb Company Fc fusion proteins comprising novel linkers or arrangements
EP2710382B1 (en) 2011-05-17 2017-10-18 Bristol-Myers Squibb Company Improved methods for the selection of binding proteins
WO2012158678A1 (en) 2011-05-17 2012-11-22 Bristol-Myers Squibb Company Methods for maintaining pegylation of polypeptides
KR102142385B1 (en) 2011-09-27 2020-08-10 얀센 바이오테크 인코포레이티드 Fibronectin type iii repeat based protein scaffolds with alternative binding surfaces
US9522951B2 (en) 2011-10-31 2016-12-20 Bristol-Myers Squibb Company Fibronectin binding domains with reduced immunogenicity
DK3835310T3 (en) 2012-09-13 2024-06-03 Bristol Myers Squibb Co FIBRONECTIN-BASED SKELETAL DOMAIN PROTEINS THAT BIND TO MYSTATIN
WO2014120891A2 (en) 2013-02-01 2014-08-07 Bristol-Myers Squibb Company Fibronectin based scaffold proteins
EP2953968B1 (en) 2013-02-06 2018-07-25 Bristol-Myers Squibb Company Fibronectin type iii domain proteins with enhanced solubility
EP3744728A1 (en) 2013-02-12 2020-12-02 Bristol-Myers Squibb Company Tangential flow filtration based protein refolding methods
EP3299378B1 (en) 2013-02-12 2019-07-31 Bristol-Myers Squibb Company High ph protein refolding methods
US9593339B1 (en) 2013-02-14 2017-03-14 David Gordon Bermudes Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment
US20160152686A1 (en) 2013-03-13 2016-06-02 Bristol-Myers Squibb Company Fibronectin based scaffold domains linked to serum albumin or moiety binding thereto
US9737592B1 (en) 2014-02-14 2017-08-22 David Gordon Bermudes Topical and orally administered protease inhibitors and bacterial vectors for the treatment of disorders and methods of treatment
KR102472862B1 (en) 2014-03-20 2022-12-05 브리스톨-마이어스 스큅 컴퍼니 Serum albumin-binding fibronectin type iii domains
AU2015231210B2 (en) 2014-03-20 2019-09-12 Bristol-Myers Squibb Company Stabilized fibronectin based scaffold molecules
ES2941895T3 (en) 2014-11-25 2023-05-26 Bristol Myers Squibb Co Methods and Compositions for 18F Radiolabeling of the Fibronectin Type (III) Domain
CN107849142B (en) 2015-05-15 2022-04-26 综合医院公司 Antagonistic anti-tumor necrosis factor receptor superfamily antibodies
ES2781207T3 (en) 2015-09-23 2020-08-31 Bristol Myers Squibb Co Serum albumin-binding fibronectin type iii domains with rapid dissociation rate
WO2017210335A1 (en) 2016-06-01 2017-12-07 Bristol-Myers Squibb Company Imaging methods using 18f-radiolabeled biologics
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
WO2018111978A1 (en) 2016-12-14 2018-06-21 Janssen Biotech, Inc. Cd137 binding fibronectin type iii domains
CA3046963A1 (en) 2016-12-14 2018-06-21 Janssen Biotech, Inc. Cd8a-binding fibronectin type iii domains
US10597438B2 (en) 2016-12-14 2020-03-24 Janssen Biotech, Inc. PD-L1 binding fibronectin type III domains
US11781138B2 (en) 2019-10-14 2023-10-10 Aro Biotherapeutics Company FN3 domain-siRNA conjugates and uses thereof
WO2021076546A1 (en) 2019-10-14 2021-04-22 Aro Biotherapeutics Company Cd71 binding fibronectin type iii domains
CN116568341A (en) 2020-02-28 2023-08-08 百时美施贵宝公司 Fibronectin-based radiolabeled scaffolds and antibodies and therapeutic diagnostic uses thereof
BR112023021325A2 (en) 2021-04-14 2023-12-19 Aro Biotherapeutics Company CD71-BINDING TYPE III FIBRONECTIN DOMAINS

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030148263A1 (en) * 1997-08-29 2003-08-07 Selective Genetics, Inc. Methods and compositions using genetic package display

Also Published As

Publication number Publication date
WO2009086116A3 (en) 2009-10-08
EP2238247A2 (en) 2010-10-13
WO2009086116A2 (en) 2009-07-09
AU2008345674A1 (en) 2009-07-09
JP2011507529A (en) 2011-03-10
CA2709994A1 (en) 2009-07-09

Similar Documents

Publication Publication Date Title
IL206409A0 (en) ALTERNATIVE SCAFFOLD PROTEIN FUSIONS PHAGE DISPLAY VIA FUSION TO pIX OF M13 PHAGE
ZA201108481B (en) L-(piperidin-4yl)-pyrazole derivatives as gpr 119 modulators
IL207161A0 (en) Methods and compositions using klotho-fgf fusion polypeptides
IL215005A0 (en) Ox40/trail fusion proteins
EP2150109A4 (en) Pharmaceutical use of substituted amides
ZA201106638B (en) Anti-angiogenic fusion proteins
AP3280A (en) Fused pyrimidine-dione derivatives as TRPA1 modulators
IL210175A0 (en) Fn14/trail fusion proteins
HK1160408A1 (en) Modulators of cxcr7 cxcr7
EP2326345A4 (en) Human notch3 based fusion proteins as decoy inhibitors of notch3 signaling
IL205716A0 (en) Formulations for taci-immunoglobulin fusion proteins
EP2237794A4 (en) Chimeric hiv fusion proteins as vaccines
IL218474A0 (en) Novel fusion proteins and method of expression thereof
PL2144924T3 (en) Fusion protein vaccine
EG26957A (en) Process for the preparation of pyrazole carboxylicacid amides
HK1150750A1 (en) Counter-pressure filtration of proteins
EP2263671A4 (en) Amide derivative-containing pharmaceutical composition
SI2401373T1 (en) Signal sequence-independent pix phage display
GB0725201D0 (en) Peptide fusion proteins
IL206334A0 (en) Sarp-i fusion proteins and their use
GB0700759D0 (en) Novel fusion protein
IL216311A0 (en) Improved coupling element for bar-shaped inverted t profiles
GB0811986D0 (en) Manufacture of non-cytotoxic fusion proteins
GB0713169D0 (en) Fusion proteins
GB0907794D0 (en) GLP 1 fusion polypeptides